$4.34
0.00%
Nasdaq, Fri, Dec 27 2024
ISIN
US55028X1090
Symbol
LUMO
Sector
Industry

Lumos Pharma Inc Stock price

$4.34
+0.04 0.93% 1M
+2.09 92.79% 6M
+1.16 36.48% YTD
+1.24 40.00% 1Y
-2.85 39.64% 3Y
-20.59 82.59% 5Y
-351.79 98.78% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.00 0.00%
ISIN
US55028X1090
Symbol
LUMO
Sector
Industry

Key metrics

Market capitalization $37.54m
Enterprise Value $30.19m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 13.66
P/S ratio (TTM) P/S ratio 16.99
P/B ratio (TTM) P/B ratio 7.64
Revenue growth (TTM) Revenue growth 26.94%
Revenue (TTM) Revenue $2.21m
EBIT (operating result TTM) EBIT $-36.33m
Free Cash Flow (TTM) Free Cash Flow $-31.67m
Cash position $13.52m
EPS (TTM) EPS $-4.28
P/E forward negative
P/S forward 49.07
EV/Sales forward 39.46
Short interest 0.87%
Show more

Is Lumos Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Lumos Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Lumos Pharma Inc forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a Lumos Pharma Inc forecast:

Buy
50%
Hold
50%

Financial data from Lumos Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2.21 2.21
27% 27%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 16 16
6% 6%
716%
- Research and Development Expense 23 23
12% 12%
1,027%
-36 -36
3% 3%
-1,643%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -36 -36
2% 2%
-1,644%
Net Profit -35 -35
6% 6%
-1,580%

In millions USD.

Don't miss a Thing! We will send you all news about Lumos Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lumos Pharma Inc Stock News

Neutral
GlobeNewsWire
17 days ago
AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures LLC (“DPV”) today announced the successful completion of the previously announced tender offer for Lumos Pharma's shares at a purchase price of (i)...
Neutral
PRNewsWire
2 months ago
NEW YORK , Oct. 23, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Lumos Pharma, Inc. (NASDAQ: LUMO) and its board of directors concerning the proposed acquisition of the company by Double Point Ventures LLC. Stockholders will receive $4.25 and one contingent value right for each share of Lumos Pharma stock that they hold.
Neutral
PRNewsWire
2 months ago
NEW YORK , Oct. 23, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Martin Midstream Partners L.P. (NASDAQ: MMLP)'s sale to Martin Resource Management Corporation for $4.02 per common unit.
More Lumos Pharma Inc News

Company Profile

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.

Head office United States
CEO Richard Hawkins
Employees 33
Founded 1999
Website www.lumos-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today